

PERSONAL INFORMATION **Javier Gisbert**WORK EXPERIENCE

- 2010- Present **Head of Inflammatory Bowel Disease Unit**
Hospital Universitario de La Princesa in Madrid (Spain)
- 2017- Present **Professor and University Chaired Professor**
Universidad Autónoma de Madrid (UAM) (Spain)
- 2007- Present **Professor of the General Directorate of Planning, Research and Training**
Ministry of Health, Madrid Autonomous Community (Spain)
- 2010- Present **Director of an autonomous line of research**
Institute for Health Research of Hospital de La Princesa (IIS-Princesa) (Spain)

EDUCATION AND TRAINING

- 1988 **MD**
Universidad Autónoma de Madrid (Spain)
- 1995 **PhD (Excellent Cum Laude)**
Universidad de Alcalá (Spain)
- 2002 **Masters**
Universidad Complutense de Madrid (Spain)

ADDITIONAL INFORMATION

Expertise

Publications

ONLY ARTICLES PUBLISHED IN THE LAST 5 YEARS IN JOURNALS OF FIRST QUARTILE (Q1) AND AS FIRST AUTHOR OR SENIOR AUTHOR ARE INCLUDED:

1. OP Nyssen; A Perez-Aisa; B Tepes; et al; JP Gisbert (AC); On behalf of the Hp-EuReg Investigators.(52/52). 2021. Adverse event profile during the treatment of Helicobacter pylori infection: a real world experience of 22,000 patients from the European Registry on H. pylori Management (Hp-EuReg).Am J Gastroenterol. 116, pp.1220-1229.
2. M.J. Casanova; M. Chaparro; O. Nantes; et al; J.P. Gisbert. (AC). (54/54). 2021. Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.Aliment Pharmacol Ther. 53, pp.21277-21288.
3. M Chaparro; A Garre; M Iborra; et al; JP Gisbert. (70/70). 2021. Effectiveness and safety of ustekinumab in ulcerative colitis: real world evidence from the ENEIDA registry.J Crohn's Colitis. 15, pp.1846-1851.
4. OP Nyssen; D Bordin; B Tepes; et al; JP Gisbert (AC); On behalf of the Hp-EuReg Investigators. (47/47). 2021. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Editor's Choice.Gut. 70-1, pp.40-54.
5. L Guberna; O P Nyssen; M Chaparro; JP Gisbert (AC). (4/4). 2021. Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: systematic review with

meta-analysis. *J Clin Med.* 10, pp.2132.

6. S Fernandez-Tome; L Ortega; M Chaparro; JP Gisbert.(4/4). 2021. Gut microbiota and dietary factors as modulators of the mucus layer in inflammatory bowel disease. *Review.Int J Mol Sci.* 22, pp.10224.
7. MJ Garcia; M Rivero; J Miranda-Bautista; et al; JP Gisbert; on behalf of the young GETECCU group.(65/65). 2021. Impact of biological agents in postsurgical complications in inflammatory bowel disease: a multicenter study of GETECCU. *J Clin Med.* 10, pp.4402.
8. M Chaparro; A Garre; A Nunez Ortiz; et al; JP Gisbert; on behalf of the EpidemIBD study group of GETECCU. (112/112). 2021. Incidence, clinical characteristics and management of inflammatory bowel disease in Spain, Large-Scale Epidemiological Study EpidemIBD. *J Clin Med.* 10, pp.2885.
9. S Fernandez-Tome; P Indiano-Romacho; I Mora-Gutierrez; et al; JP Gisbert (shared senior author); D Bernardo.(12/13). 2021. Lunasin peptide is a modulator of the immune response in the human gastrointestinal tract. *Mol Nutr Food Res.* 65, pp.e2001034.
10. Aldars-Garcia; JP Gisbert (shared senior author); M Chaparro. (2/3). 2021. Metabolomics insights into Inflammatory Bowel Disease: A Comprehensive Review. *Pharmaceuticals.* 14, pp.1190.
11. JP Gisbert (AC); M Chaparro.(1/2). 2021. Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)?. *J Clin Med.* 10, pp.5318.
12. LG Guijarro; D Cano-Martinez; MV Toledo-Lobo; et al; JP Gisbert (shared senior author) (AC); B Hernandez-Breijo.(28/30). 2021. Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. *Biomed Pharmacother.* 144, pp.:112239.
13. L Aldars-Garcia; AC Marin; M Chaparro; JP Gisbert.(4/4). 2021. The Interplay Between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. *Int J Mol Sci.* 22, pp.3076.
14. M Chaparro; A Garre; F Mesonero; et al; JP Gisbert.(40/40). 2021. Tofacitinib in ulcerative colitis: real world evidence from ENEIDA registry. *J Crohns Colitis.* 15, pp.35-42.
15. M Chaparro; J Gordillo; E Domenech; et al; JP Gisbert. (18/18). 2020. Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. *Am J Gastroenterol.* 115-11, pp.1802-1811.
16. JP Gisbert (AC); M Chaparro. (1/2). 2020. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. *J Crohns Colitis.* 14-5, pp.694-709.
17. G Fiorino; T Lytras; L Younge; et al; JP Gisbert; on behalf of the European Crohn's Colitis Organisation (ECCO). (28/28). 2020. Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. *J Crohn's Colitis.* 14-8, pp.1037-1048.
18. JP Gisbert (AC); M Chaparro. (1/2). 2020. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. *Drugs.* 80, pp.1085-1100.
19. L Ortega Moreno; Ancor Sanz-Garcia; MJ Fernandez de la Fuente; et al; JP Gisbert (shared senior author); D Bernardo. (11/12). 2020. Serum adipokines as non-invasive biomarkers in Crohn's disease. *Scientific Reports.* 10-1, pp.18027.
20. I Rodriguez-Lago; J Castro-Poceiro; A Fernandez-Clotet; et al; JP Gisbert. (AC). (30/30). 2020. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. *Aliment Pharmacol Ther.* 51, pp.870-879.
21. I. Rodriguez-Lago; JP. Gisbert (AC). (2/2). 2020. The role of immunomodulators and biologics in the medical management of stricturing Crohn's disease. *J Crohn's Colitis.* 14, pp.557-566.
22. Guerra, I.; Bujanda, L.; Castro, J.; et al; Gisbert, JP.(77/77). 2019. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. *Journal of Crohn's & colitis.* 13-12, pp.1492-1500.
23. Fernandez Tome, S.; Marin, AC.; Ortega Moreno, L.; et al; Gisbert, JP. (shared senior author); Bernardo, D.(11/12). 2019. Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease. *Nutrients.* 11-11, pp.2605.
24. Chaparro, M.; Garre, A.; Guerra Veloz, MF.; et al; Gisbert, JP.(31/31). 2019. Effectiveness and Safety of the Switch from Remicade(R) to CT-P13 in Patients with Inflammatory Bowel Disease. *Journal of Crohn's & colitis.* 13-11, pp.1380-1386.

25. Chavarria, C.; Casanova, MJ.; Chaparro, M.; et al; Gisbert, JP. (AC). (33/33). 2019. Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study. *Journal of Crohn's & colitis*. 13-8, pp.996-1002.
26. McNicholl, AG.; Bordin, DS.; Lucendo, A.; et al; Gisbert, JP. (AC). (36/36). 2019. Combination of Bismuth and Standard Triple Therapy Eradicates *Helicobacter pylori* Infection in More than 90% of Patients. *Clinical Gastroenterology and Hepatology*. 18-1, pp.89-98.
27. Gisbert, JP. (AC); Chaparro, M.(1/2). 2019. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. *Journal of Crohn's & colitis*. 13-3, pp.374-384.
28. Chaparro, M.; Garre, A.; Ricart, E.; Iglesias Flores, E.; Taxonera, C.; Domenech, E.; Gisbert, JP.(7/7). 2019. Differences between childhood and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. *Alimentary pharmacology & therapeutics*. 49-4, pp.419-428.
29. Fiorino, G.; Allocca, M.; Chaparro, M.; Coenen, S.; Fidalgo, C.; Younge, L.; Gisbert, JP.(7/7). 2019. 'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. *Journal of Crohn's & colitis*. 13-1, pp.127-137.
30. S Fernandez-Tome; B Hernandez-Ledesma; M Chaparro; P Indiano-Romacho; D Bernardo; JP Gisbert. (6/6). 2019. Role of food proteins and bioactive peptides in inflammatory bowel disease. *Trends in Food Science & Technology*. 2019-88, pp.194-206.
31. Bernardo, D.; Chaparro, M.; Gisbert, JP.(3/3). 2018. Human Intestinal Dendritic Cells in Inflammatory Bowel Diseases. *Molecular nutrition & food research*. 62-7, pp.e1700931.
32. Chaparro, M.; Verreth, A.; Lobaton, T.; et al; Gisbert, JP.(64/64). 2018. Long-Term Safety of In Utero Exposure to Anti-TNF? Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. *The American journal of gastroenterology*. 113-3, pp.396-403.
33. O Companioni; C Bonet; N Garcia; et al; JP Gisbert (shared senior author); N Sala. (25/27). 2018. Genetic variation analysis in a follow-up study of gastric cancer precursor lesions confirms the association of MUC2 variants with the evolution of the lesions and identifies a significant association with NFKB1 and CD14. *Int J Cancer*. 43-11, pp.2777-2786.
34. Molina-Infante J; Gutierrez-Junquera C; Savarino E; et al; Gisbert JP (shared senior author); Upper GI Tract Study Group from the Spanish Gastroenterological Association (AEG).(17/18). 2018. *Helicobacter pylori* infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. *Am J Gastroenterol*. 113-7, pp.972-979.
35. D Bernardo; AC Marin; S Fernandez-Tome; et al; JP Gisbert. (19/19). 2018. Human intestinal pro-inflammatory CD11c^{high}CCR2⁺CX3CR1⁺ macrophages, but not their tolerogenic CD11c⁻CCR2⁻CX3CR1⁻ counterparts, are expanded in inflammatory bowel disease. *Mucosal Immunol*. 11-4, pp.1114-1126.
36. S Fernandez-Tome; A Montalban-Arques; A Diaz-Guerra; et al; JP Gisbert (shared senior author) (AC); D Bernardo. (11/12). 2018. Peptides encrypted in the human intestinal microbial-exoproteome 1 as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract. *Journal of Functional Foods*. 52, pp.459-468.
37. C Taxonera; A Ponferrada; S Riestra; et al; JP Gisbert.(27/27). 2018. Serial Tuberculin Skin Tests Improves the Detection of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. *J Crohns Colitis*. 15-12(11), pp.1270-1279.
38. M Chaparro; M Sierra-Ausin; F Mesonero; et al; JP Gisbert. (32/32). 2018. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. *Aliment Pharmacol Ther*. 48, pp.839-851.
39. Casanova, MJ.; Chaparro, M.; Molina, B.; et al; Gisbert, JP. (AC). (60/60). 2017. Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. *J Crohns Colitis*. 11-12, pp.1430-1439.
40. McNicholl, AG.; Gisbert, JP. (AC). (2/2). 2017. Research to the N-Power: The Strengths of Networked Clinical Collaboration in Spain. *Am J Gastroenterol*. 112-12, pp.1761-1764.
41. Chaparro, M.; Ramas, M.; Benitez, JM.; et al; Gisbert, JP.(29/29). 2017. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. *Am J Gastroenterol*. 112-7, pp.1135-1143.
42. Marin, AC.; Nyssen, OP.; McNicholl, AG.; Gisbert, JP.(4/4). 2017. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for *Helicobacter pylori* Eradication: Systematic Review and Meta-Analysis. *Drugs*. 77-7, pp.765-776.
43. Taxonera, C.; Ponferrada, A.; Bermejo, F.; et al; Gisbert, JP.(23/23). 2017. Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel

Disease. J Crohns Colitis. 11, pp.792-800.

44. Casanova, MJ.; Chaparro, M.; Garcia Sanchez, V.; et al; Gisbert, JP. (AC). (84/84). 2017. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Am J Gastroenterol. 112-1, pp.120-131.

Projects

Founder of the Collaborative Research Platform in Gastroenterology of the Spanish Association of Gastroenterology (AEG-REDCap; Project-REDCap International consortium).

Coordinator of various large-scale collaboration networks that include gastroenterologists from more than 100 Spanish hospitals and 250 international centers,

Memberships

Member of Research Committee and the Biological Therapies Unit at Hospital de La Princesa

Member (past President) of the research committee (ClinCom) of the European Crohn's and Colitis Organisation (ECCO), the European Helicobacter and Microbiota Study Group (EHMSG) and responsible for the research area of GETECCU,

Member of the Clinical Guidelines Committee (GuiCom) and the Steering Committee of UR-CARE (United Registries of Clinical Assessment and Research) of the Crohn's and Colitis Organization (ECCO).

Member of the Council/Editorial Committee of >10 scientific journals, as well as International Editor of the Cochrane Collaboration and advisor of the International Agency for Research on Cancer (IARC, World Health Organization).

Other Relevant Information